- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
BriaCell
TSX:BCT
Developing Personalized Off-The-Shelf Immunotherapy Treatments for Cancer Patients
​Company Highlights
- BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer.
- BriaCell has partnered with Waisman Biomanufacturing to manufacture and supply prostate cancer immunotherapy
- The company has entered a research agreement with Harvard Medical School in support of a project led by Joan S. Brugge to identify Novel targets for cancer treatment
- BriaCell secured an exclusive license from the University of Maryland, Baltimore County (UMBC) to develop and commercialize Soluble CD80 (sCD80) as a biologic agent for the treatment of cancer.
- BriaCell signed an agreement with Caris Life Sciences to develop immunotherapies that are personalized for each patient by expanding patient outreach and molecular profiling.
- BriaCell’s lead drug candidate Bria-IMT™ is targeting third-line advanced breast cancer with Phase I/IIa safety and efficacy showing similar or superior results to other advanced or approved drugs at a comparable stage
- The company plans to initiate a registration study on Bria-IMTâ„¢ combined with an immune checkpoint inhibitor during the first quarter of 2023.
- BriaCell’s clinical strategy team is involved in 19 drug approvals
- Bria-OTSâ„¢, is currently being manufactured at a cGMP facility and undergoing quality control testing for the potential upcoming clinical trial for patients with advanced breast cancer.
- BriaCell has received fast track status for Bria-IMTâ„¢ from the US Food and Drug Administration (FDA).
Press Releases
More Press Releases
Overview
BriaCell Therapeutics (NASDAQ:BCTX, BCTXW;TSX:BCT) is a clinical-phase biotechnology company developing innovative immunotherapies for treating cancer.
At the forefront of cancer treatments, immunotherapies boost the ability of the body's own cancer-fighting cells to destroy cancerous tumors. Immunotherapies also have low-toxicity, making it easier for patients to undergo treatment. Most importantly, they may offer better efficacy and less chance of recurrence for many cancer patients. A report released by Research and Markets says the global immuno-oncology market is expected to reach US$135 billion by 2024. BriaCell continues to uncover opportunities in this space with its innovative technologies.Company Highlights
- BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer.
- BriaCell has partnered with Waisman Biomanufacturing to manufacture and supply prostate cancer immunotherapy
- The company has entered a research agreement with Harvard Medical School in support of a project led by Joan S. Brugge to identify Novel targets for cancer treatment
- BriaCell secured an exclusive license from the University of Maryland, Baltimore County (UMBC) to develop and commercialize Soluble CD80 (sCD80) as a biologic agent for the treatment of cancer.
- BriaCell signed an agreement with Caris Life Sciences to develop immunotherapies that are personalized for each patient by expanding patient outreach and molecular profiling.
- BriaCell’s lead drug candidate Bria-IMT™ is targeting third-line advanced breast cancer with Phase I/IIa safety and efficacy showing similar or superior results to other advanced or approved drugs at a comparable stage
- The company plans to initiate a registration study on Bria-IMTâ„¢ combined with an immune checkpoint inhibitor during the first quarter of 2023.
- BriaCell’s clinical strategy team is involved in 19 drug approvals
- Bria-OTSâ„¢, is currently being manufactured at a cGMP facility and undergoing quality control testing for the potential upcoming clinical trial for patients with advanced breast cancer.
- BriaCell has received fast track status for Bria-IMTâ„¢ from the US Food and Drug Administration (FDA).
Interactive Chart
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â